{"nctId":"NCT01890434","briefTitle":"Gadobutrol / Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)","startDateStruct":{"date":"2013-08-26","type":"ACTUAL"},"conditions":["Coronary Artery Disease"],"count":478,"armGroups":[{"label":"Gadobutrol 0.1 mmol/kg body weight","type":"EXPERIMENTAL","interventionNames":["Drug: Gadobutrol (Gadavist, Gadovist, BAY86-4875)"]}],"interventions":[{"name":"Gadobutrol (Gadavist, Gadovist, BAY86-4875)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female subjects aged ≥18 years\n* Subjects with suspected or known CAD based on signs and/or (typical or atypical) chest pain who have routine CA without intervention within plus/minus 4 weeks of gadobutrol-enhanced CMRI or subjects at low risk of CAD with / or scheduled to get a CTA for the purpose of exclusion of CAD within plus/minus 6 weeks of gadobutrol-enhanced CMRI\n* Willingness to undergo unenhanced wall motion and gadobutrol-enhanced CMRI at stress/rest and gated single photon emission computed tomography (GSPECT, if GSPECT will be a study procedure)\n* Women of childbearing potential (e.g. age \\< 60y, no history of surgical sterilization or hysterectomy): use of contraception and a negative pregnancy test\n* Subjects who are scheduled for / have undergone routine GSPECT or undergo GSPECT as a study procedure at stress and at rest within ± 4 weeks of gadobutrol-enhanced CMRI\n\nExclusion Criteria:\n\n* Suspected clinical instability or unpredictability of the clinical course during the study period\n* Contraindication to the cardiac MRI examination (e.g. inability to hold breath; severe claustrophobia, metallic devices such as pace makers)\n* History of severe allergic or anaphylactoid reaction to any allergen including drugs and contrast agents according to the investigator's assessment / judgment\n* Estimated glomerular filtration rate (eGFR) value \\<30 mL/min/1.73 m\\^2 derived from a serum / blood creatinine result within 2 weeks prior to gadobutrol injection. Any subject on hemodialysis or peritoneal dialysis is excluded from enrollment.\n* Acute renal insufficiency\n* Coronary artery bypass grafting (CABG)\n* Acute myocardial infarction (\\< 14 days prior to inclusion), unstable angina / acute coronary syndrome, severe congestive heart failure\n* Irregular heart rhythm\n* Condition that precludes the safe administration of pharmacological stressor according to the respective approved label such as sinus node disease, 2nd or 3rd degree atrioventricular block, obstructive lung disease","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI - Primary Analysis of Sensitivity Based on Blinded Readers' Assessment","description":"Blinded readers evaluated 6 myocardial regions based on regional perfusion score \\[RPS: 0=normal; 1=abnormal, reversible perfusion defect (stress); 2=abnormal, mixed perfusion defect (reversible and fixed/permanent components); 3=abnormal, fixed/permanent perfusion defect/scar (stress and rest)\\]. A myocardial region was rated to have a perfusion defect in case of a RPS of \\>=1 and was rated to have normal perfusion in case of a RPS of 0. Significant CAD was defined as quantitative coronary angiography (QCA) stenosis of \\>=50% for primary analysis, and was determined based on the presence of a myocardial perfusion defect on gadobutrol-enhanced cardiac magnetic resonance imaging (CMRI) verified by standard of reference (SoR, coronary angiography \\[CA\\] or computed tomography angiography \\[CTA, only if disease can be unequivocally rejected\\]). Sensitivity= true positive/ (true positive + false negative).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI - Additional Secondary Analysis of Sensitivity Based on Blinded Readers' Assessment","description":"Blinded readers evaluated 6 myocardial regions based on regional perfusion score \\[RPS: 0=normal; 1=abnormal, reversible perfusion defect (stress); 2=abnormal, mixed perfusion defect (reversible and fixed/permanent components); 3=abnormal, fixed/permanent perfusion defect/scar (stress and rest)\\]. A myocardial region was rated to have a perfusion defect in case of a RPS of \\>=1 and was rated to have normal perfusion in case of a RPS of 0. Significant CAD was defined as QCA stenosis of \\>=70%, and was determined based on the presence of a myocardial perfusion defect on gadobutrol-enhanced CMRI verified by SoR (CA or CTA \\[only if disease can be unequivocally rejected\\]). Sensitivity= true positive/ (true positive + false negative). This additional secondary analysis of sensitivity was retrospective analysis.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.2","spread":null}]}]}]},{"type":"PRIMARY","title":"Absence of Myocardial Perfusion Defect Excluding Significant CAD Per Participant on Gadobutrol-enhanced CMRI - Primary Analysis of Specificity Based on Blinded Readers' Assessment","description":"Blinded readers evaluated 6 myocardial regions based on regional perfusion score \\[RPS: 0=normal; 1=abnormal, reversible perfusion defect (stress); 2=abnormal, mixed perfusion defect (reversible and fixed/permanent components); 3=abnormal, fixed/permanent perfusion defect/scar (stress and rest)\\]. A myocardial region was rated to have a perfusion defect in case of a RPS of \\>=1 and was rated to have normal perfusion in case of a RPS of 0. Significant CAD was defined as QCA stenosis of \\>=50% for primary analysis, and was determined based on the presence of a myocardial perfusion defect on gadobutrol-enhanced CMRI verified by SoR (CA or CTA \\[only if disease can be unequivocally rejected\\]). Specificity= true negative/ (true negative + false positive).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.5","spread":null}]}]}]},{"type":"PRIMARY","title":"Absence of a Myocardial Perfusion Defect Excluding Significant CAD Per Participant on Gadobutrol-enhanced CMRI - Additional Secondary Analysis of Specificity Based on Blinded Readers' Assessment","description":"Blinded readers evaluated 6 myocardial regions based on regional perfusion score \\[RPS: 0=normal; 1=abnormal, reversible perfusion defect (stress); 2=abnormal, mixed perfusion defect (reversible and fixed/permanent components); 3=abnormal, fixed/permanent perfusion defect/scar (stress and rest)\\]. A myocardial region was rated to have a perfusion defect in case of a RPS of \\>=1 and was rated to have normal perfusion in case of a RPS of 0. Significant CAD was defined as QCA stenosis of \\>=70%, and was determined based on the presence of a myocardial perfusion defect on gadobutrol-enhanced CMRI verified by SoR (CA or CTA \\[only if disease can be unequivocally rejected\\]). Specificity= true negative/ (true negative + false positive). This additional secondary analysis of specificity was retrospective analysis.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.9","spread":null}]}]}]},{"type":"PRIMARY","title":"Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI Versus Unenhanced Wall Motion CMRI Images - Primary Analysis of Sensitivity Comparison Based on the Blinded Readers' Assessment","description":"Presence of a myocardial perfusion defect on gadobutrol-enhanced CMRI versus the presence of wall motion abnormalities on unenhanced CMRI images (based on regional perfusion/regional wall motion score of the 6 myocardial regions) was calculated by blinded readers' assessment. Significant CAD was defined as QCA stenosis of \\>=50% for primary analysis, and was determined based on the presence of a myocardial perfusion defect on gadobutrol-enhanced CMRI or the presence of wall motion abnormalities on unenhanced CMRI images verified by SoR (CA or CTA \\[only if disease can be unequivocally rejected\\]). Sensitivity= true positive/ (true positive + false negative).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI Versus Unenhanced Wall Motion CMRI Images - Additional Secondary Analysis of Sensitivity Comparison Based on the Blinded Readers' Assessment","description":"Presence of a myocardial perfusion defect on gadobutrol-enhanced CMRI versus the presence of wall motion abnormalities on unenhanced CMRI images (based on regional perfusion/regional wall motion score of the 6 myocardial regions) was calculated by blinded readers' assessment. Significant CAD was defined as QCA stenosis of \\>=70%, and was determined based on the presence of a myocardial perfusion defect on gadobutrol-enhanced CMRI or the presence of wall motion abnormalities on unenhanced CMRI images verified by SoR (CA or CTA \\[only if disease can be unequivocally rejected\\]). Sensitivity= true positive/ (true positive + false negative). This additional secondary analysis of sensitivity was retrospective analysis.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI - Secondary Analysis of Sensitivity Based on Investigator's Assessment","description":"The investigator evaluated 6 myocardial regions based on regional perfusion score \\[RPS: 0=normal; 1=abnormal, reversible perfusion defect (stress); 2=abnormal, mixed perfusion defect (reversible and fixed/permanent components); 3=abnormal, fixed/permanent perfusion defect/scar (stress and rest)\\]. A myocardial region was rated to have a perfusion defect in case of a RPS of \\>=1 and was rated to have normal perfusion in case of a RPS of 0. Significant CAD was defined as QCA stenosis of \\>=50%, and was determined based on the presence of a myocardial perfusion defect on gadobutrol-enhanced CMRI verified by SoR (CA or CTA \\[only if disease can be unequivocally rejected\\]). Sensitivity= true positive/ (true positive + false negative).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI - Additional Secondary Analysis of Sensitivity Based on Investigator's Assessment","description":"The investigator evaluated 6 myocardial regions based on regional perfusion score \\[RPS: 0=normal; 1=abnormal, reversible perfusion defect (stress); 2=abnormal, mixed perfusion defect (reversible and fixed/permanent components); 3=abnormal, fixed/permanent perfusion defect/scar (stress and rest)\\]. A myocardial region was rated to have a perfusion defect in case of a RPS of \\>=1 and was rated to have normal perfusion in case of a RPS of 0. Significant CAD was defined as QCA stenosis of \\>=70%, and was determined based on the presence of a myocardial perfusion defect on gadobutrol-enhanced CMRI verified by SoR (CA or CTA \\[only if disease can be unequivocally rejected\\]). Sensitivity= true positive/ (true positive + false negative). This additional secondary analysis of sensitivity was retrospective analysis.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Absence of a Myocardial Perfusion Defect Excluding Significant CAD Per Participant on Gadobutrol-enhanced CMRI - Secondary Analysis of Specificity Based on Investigator's Assessment","description":"The investigator evaluated 6 myocardial regions based on regional perfusion score \\[RPS: 0=normal; 1=abnormal, reversible perfusion defect (stress); 2=abnormal, mixed perfusion defect (reversible and fixed/permanent components); 3=abnormal, fixed/permanent perfusion defect/scar (stress and rest)\\]. A myocardial region was rated to have a perfusion defect in case of a RPS of \\>=1 and was rated to have normal perfusion in case of a RPS of 0. Significant CAD was defined as QCA stenosis of \\>=50%, and was determined based on the presence of a myocardial perfusion defect on gadobutrol-enhanced CMRI verified by SoR (CA or CTA \\[only if disease can be unequivocally rejected\\]). Specificity= true negative/ (true negative + false positive).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Absence of a Myocardial Perfusion Defect Excluding Significant CAD Per Participant on Gadobutrol-enhanced CMRI - Additional Secondary Analysis of Specificity Based on Investigator's Assessment","description":"The investigator evaluated 6 myocardial regions based on regional perfusion score \\[RPS: 0=normal; 1=abnormal, reversible perfusion defect (stress); 2=abnormal, mixed perfusion defect (reversible and fixed/permanent components); 3=abnormal, fixed/permanent perfusion defect/scar (stress and rest)\\]. A myocardial region was rated to have a perfusion defect in case of a RPS of \\>=1 and was rated to have normal perfusion in case of a RPS of 0. Significant CAD was defined as QCA stenosis of \\>=70%, and was determined based on the presence of a myocardial perfusion defect on gadobutrol-enhanced CMRI verified by SoR (CA or CTA \\[only if disease can be unequivocally rejected\\]). Specificity= true negative/ (true negative + false positive). This additional secondary analysis of specificity was retrospective analysis.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI Versus Unenhanced Wall Motion CMRI Images - Secondary Analysis of Sensitivity Comparison Based on the Investigator's Assessment","description":"Presence of a myocardial perfusion defect on gadobutrol-enhanced CMRI versus the presence of wall motion abnormalities on unenhanced CMRI images (based on regional perfusion/regional wall motion score of the 6 myocardial regions) was calculated by investigator's assessment. Significant CAD was defined as QCA stenosis of \\>=50%, and was determined based on the presence of a myocardial perfusion defect on gadobutrol-enhanced CMRI or the presence of wall motion abnormalities on unenhanced CMRI images verified by SoR (CA or CTA \\[only if disease can be unequivocally rejected\\]). Sensitivity= true positive/ (true positive + false negative).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI and Unenhanced Wall Motion CMRI Images - Additional Secondary Analysis of Sensitivity Comparison Based on the Investigator's Assessment","description":"Presence of a myocardial perfusion defect on gadobutrol-enhanced CMRI versus the presence of wall motion abnormalities on unenhanced CMRI images (based on regional perfusion/regional wall motion score of the 6 myocardial regions) was calculated by investigator's assessment. Significant CAD was defined as QCA stenosis of \\>=70%, and was determined based on the presence of a myocardial perfusion defect on gadobutrol-enhanced CMRI or the presence of wall motion abnormalities on unenhanced CMRI images verified by SoR (CA or CTA \\[only if disease can be unequivocally rejected\\]). Sensitivity= true positive/ (true positive + false negative). This additional secondary analysis of sensitivity was retrospective analysis.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI Versus GSPECT - Secondary Analysis of Sensitivity Comparison Based on Majority Blinded Reader's and Investigator's Assessment","description":"Presence of a myocardial perfusion defect on gadobutrol-enhanced CMRI versus GSPECT (based on RPS of the 6 myocardial regions) was calculated by majority blinded reader (BR) and investigator's assessment. Significant CAD was defined as QCA stenosis of \\>=50%, and was determined based on the presence of a myocardial perfusion defect on gadobutrol-enhanced CMRI or GSPECT verified by SoR (CA or CTA \\[only if disease can be unequivocally rejected\\]). Sensitivity= true positive/ (true positive + false negative). Blinded reading of the gadobutrol-enhanced CMRI images and GSPECT images was performed by different readers.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI and GSPECT - Additional Secondary Analysis of Sensitivity Based on Majority Blinded Reader's and Investigator's Assessment","description":"Presence of a myocardial perfusion defect on gadobutrol-enhanced CMRI versus GSPECT (based on RPS of the 6 myocardial regions) was calculated by majority blinded reader and investigator's assessment. Significant CAD was defined as QCA stenosis of \\>=70%, and was determined based on the presence of a myocardial perfusion defect on gadobutrol-enhanced CMRI or GSPECT verified by SoR (CA or CTA \\[only if disease can be unequivocally rejected\\]). Sensitivity= true positive/ (true positive + false negative). This additional secondary analysis of sensitivity was retrospective analysis. Blinded reading of the gadobutrol-enhanced CMRI images and GSPECT images was performed by different readers.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Absence of a Myocardial Perfusion Defect Excluding Significant CAD Per Participant on Gadobutrol-enhanced CMRI Versus GSPECT -- Secondary Analysis of Specificity Comparison Based on Majority Blinded Reader's and Investigator's Assessment","description":"Absence of a myocardial perfusion defect on gadobutrol-enhanced CMRI versus GSPECT (based on RPS of the 6 myocardial regions) was calculated by majority blinded reader and investigator's assessment. Significant CAD was defined as QCA stenosis of \\>=50%, and was determined based on the presence of a myocardial perfusion defect on gadobutrol-enhanced CMRI or GSPECT verified by SoR (CA or CTA \\[only if disease can be unequivocally rejected\\]). Specificity= true negative/(true negative + false positive). Blinded reading of the gadobutrol-enhanced CMRI images and GSPECT images was performed by different readers.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Absence of a Myocardial Perfusion Defect Excluding Significant CAD Per Participant on Gadobutrol-enhanced CMRI and GSPECT - Additional Secondary Analysis of Specificity Based on Majority Blinded Reader's and Investigator's Assessment","description":"Absence of a myocardial perfusion defect on gadobutrol-enhanced CMRI versus GSPECT (based on RPS of the 6 myocardial regions) was calculated by majority blinded reader and investigator's assessment. Significant CAD was defined as QCA stenosis of \\>=70%, and was determined based on the presence of a myocardial perfusion defect on gadobutrol-enhanced CMRI or GSPECT verified by SoR (CA or CTA \\[only if disease can be unequivocally rejected\\]). Specificity= true negative/(true negative + false positive). This additional secondary analysis of specificity was retrospective analysis. Blinded reading of the gadobutrol-enhanced CMRI images and GSPECT images was performed by different readers.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Localization of a Myocardial Perfusion Defect to Each Coronary Territory on Gadobutrol-enhanced CMRI - Secondary Analysis of Sensitivity Based on Blinded Readers' and Investigator's Assessment","description":"Sensitivity was calculated coronary territory based, a coronary territory (left anterior descending artery \\[LAD\\] / non-LAD / right coronary artery \\[RCA\\] / left circumflex artery \\[LCX\\]) was rated positive for significant CAD (significant CAD defined as QCA stenosis of\\>=50%), if \\>=1 myocardial region within the same coronary territory showed a myocardial perfusion defect with a RPS of \\>=1. A coronary territory (LAD / non-LAD) was rated negative for significant CAD, if no myocardial region within the respective coronary territory showed a myocardial perfusion defect (RPS 0). Sensitivity was displayed for all 3 blinded readers, majority blinded reader and the investigator.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Localization of a Myocardial Perfusion Defect to LAD and Non-LAD Territory on GSPECT - Secondary Analysis of Sensitivity Based on Blinded Readers' and Investigator's Assessment","description":"Sensitivity was calculated coronary territory based, a coronary territory (LAD / non-LAD) was rated positive for significant CAD (significant CAD defined as QCA stenosis of \\>=50%), if \\>=1 myocardial region within the same coronary territory showed a myocardial perfusion defect with a RPS of \\>=1. A coronary territory (LAD / non-LAD) was rated negative for significant CAD, if no myocardial region within the respective coronary territory showed a myocardial perfusion defect (RPS 0). Sensitivity was displayed for all 3 blinded readers, majority blinded reader and the investigator. Blinded reading of the gadobutrol-enhanced CMRI images and GSPECT images was performed by different readers.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Localization of a Myocardial Perfusion Defect to Each Coronary Territory on Gadobutrol-enhanced CMRI - Additional Secondary Analysis of Sensitivity Based on Blinded Readers' and Investigator's Assessment","description":"Sensitivity was calculated coronary territory based, a coronary territory (LAD / non-LAD / RCA / LCX) was rated positive for significant CAD (significant CAD defined as QCA stenosis of \\>=70%), if \\>=1 myocardial region within the same coronary territory showed a myocardial perfusion defect with a RPS of \\>=1. A coronary territory (LAD / non-LAD) was rated negative for significant CAD, if no myocardial region within the respective coronary territory showed a myocardial perfusion defect (RPS 0). Sensitivity was displayed for all 3 blinded readers and the investigator. This additional secondary analysis of sensitivity was retrospective analysis.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Localization of a Myocardial Perfusion Defect to Each Coronary Territory on Gadobutrol-enhanced CMRI - Secondary Analysis of Specificity Based on Blinded Readers' and Investigator's Assessment","description":"Specificity was calculated coronary territory based, a coronary territory (LAD / non-LAD / RCA / LCX) was rated positive for significant CAD (significant CAD defined as QCA stenosis of \\>=50%), if \\>=1 myocardial region within the same coronary territory showed a myocardial perfusion defect with a RPS of \\>=1. A coronary territory (LAD / non-LAD) was rated negative for significant CAD, if no myocardial region within the respective coronary territory showed a myocardial perfusion defect (RPS 0). Specificity was displayed for all 3 blinded readers and the investigator.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Localization of a Myocardial Perfusion Defect to LAD and Non-LAD Territory on GSPECT - Secondary Analysis of Specificity Based on Blinded Readers' and Investigator's Assessment","description":"Specificity was calculated coronary territory based, a coronary territory (LAD / non-LAD) was rated positive for significant CAD (significant CAD defined as QCA stenosis of \\>=50%), if \\>=1 myocardial region within the same coronary territory showed a myocardial perfusion defect with a RPS of \\>=1. A coronary territory (LAD / non-LAD) was rated negative for significant CAD, if no myocardial region within the respective coronary territory showed a myocardial perfusion defect (RPS 0). Specificity was displayed for all 3 blinded readers, majority blinded reader and the investigator. Blinded reading of the gadobutrol-enhanced CMRI images and GSPECT images was performed by different readers.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Localization of a Myocardial Perfusion Defect to Each Coronary Territory on Gadobutrol-enhanced CMRI - Additional Secondary Analysis of Specificity Based on Blinded Readers' and Investigator's Assessment","description":"Specificity was calculated coronary territory based, a coronary territory (LAD / non-LAD / RCA / LCX) was rated positive for significant CAD (significant CAD defined as QCA stenosis of \\>=70%), if \\>=1 myocardial region within the same coronary territory showed a myocardial perfusion defect with a RPS of \\>=1. A coronary territory (LAD / non-LAD) was rated negative for significant CAD, if no myocardial region within the respective coronary territory showed a myocardial perfusion defect (RPS 0). Specificity was displayed for all 3 blinded readers and the investigator. This additional secondary analysis of specificity was retrospective analysis.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Detection of Myocardial Perfusion Defect(s) on Gadobutrol-enhanced CMRI in Participants With Significant LMS Stenosis - Based on Blinded Readers' and Investigator's Assessment","description":"Number of participants with myocardial perfusion defects on gadobutrol-enhanced CMRI was calculated in participants with significant left main stem (LMS) stenosis and the myocardial perfusion defect pattern was described. If \\>=1 myocardial region showed a myocardial perfusion defect with a RPS of \\>=1, participants will be rated positive for significant CAD (significant CAD defined as QCA stenosis of \\>=50%).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Presence of a Myocardial Perfusion Defect Indicating Significant CAD in Participants With Single or Multi-vessel Disease Evaluated on Gadobutrol-enhanced CMRI - Secondary Analysis of Sensitivity Based on Blinded Readers' and Investigator's Assessment","description":"Sensitivity was calculated for detection of myocardial perfusion defects on gadobutrol-enhanced CMRI in participants with single and multi-vessel diseases. If \\>=1 myocardial region showed a myocardial perfusion defect with a RPS of \\>=1, participants will be rated positive for significant CAD (significant CAD defined as QCA stenosis of \\>=50%). Sensitivity= true positive/ (true positive + false negative).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Presence of a Myocardial Perfusion Defect Indicating Significant CAD in Participants With Single-vessel Disease Evaluated on Gadobutrol-enhanced CMRI and GSPECT - Additional Secondary Analysis of Sensitivity by Majority Blinded Reader and Investigator","description":"Sensitivity was calculated for detection of myocardial perfusion defects on gadobutrol-enhanced CMRI and GSPECT in participants with single-vessel diseases. If \\>=1 myocardial region showed a myocardial perfusion defect with a RPS of \\>=1, participants will be rated positive for significant CAD (significant CAD defined as QCA stenosis of \\>=70%). Sensitivity= true positive/ (true positive + false negative). This additional secondary analysis of sensitivity was retrospective analysis. Blinded reading of the gadobutrol-enhanced CMRI images and GSPECT images was performed by different readers.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Presence of a Myocardial Perfusion Defect Indicating Significant CAD in Participants With Multi-vessel Disease Evaluated on Gadobutrol-enhanced CMRI and GSPECT - Additional Secondary Analysis of Sensitivity by Majority Blinded Reader and Investigator","description":"Sensitivity was calculated for detection of myocardial perfusion defects on gadobutrol-enhanced CMRI and GSPECT in participants with single-vessel diseases. If \\>=1 myocardial region showed a myocardial perfusion defect with a RPS of \\>=1, participants will be rated positive for significant CAD (significant CAD defined as QCA stenosis of \\>=70%). Sensitivity= true positive/ (true positive + false negative). This additional secondary analysis of sensitivity was retrospective analysis. Blinded reading of the gadobutrol-enhanced CMRI images and GSPECT images was performed by different readers.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants by Their Lowest Confidence in Diagnosis Obtained on Gadobutrol-enhanced CMRI and Unenhanced Wall Motion CMRI - Based on Blinded Readers' and Investigator's Assessment","description":"Score for confidence in diagnosis (not confident, somewhat confident, and confident) was described descriptively for each of the 6 myocardial regions. The frequency over the worst confidence in diagnosis obtained within a participant was displayed. All these analyses were done separately for gadobutrol-enhanced CMRI and unenhanced wall motion CMRI.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"310","spread":null}]},{"measurements":[{"groupId":"OG000","value":"74","spread":null}]},{"measurements":[{"groupId":"OG000","value":"4","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"300","spread":null}]},{"measurements":[{"groupId":"OG000","value":"71","spread":null}]},{"measurements":[{"groupId":"OG000","value":"17","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"186","spread":null}]},{"measurements":[{"groupId":"OG000","value":"155","spread":null}]},{"measurements":[{"groupId":"OG000","value":"47","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"274","spread":null}]},{"measurements":[{"groupId":"OG000","value":"98","spread":null}]},{"measurements":[{"groupId":"OG000","value":"17","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"315","spread":null}]},{"measurements":[{"groupId":"OG000","value":"72","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"290","spread":null}]},{"measurements":[{"groupId":"OG000","value":"84","spread":null}]},{"measurements":[{"groupId":"OG000","value":"14","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"329","spread":null}]},{"measurements":[{"groupId":"OG000","value":"44","spread":null}]},{"measurements":[{"groupId":"OG000","value":"15","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"341","spread":null}]},{"measurements":[{"groupId":"OG000","value":"46","spread":null}]},{"measurements":[{"groupId":"OG000","value":"2","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":478},"commonTop":["Headache","Nausea","Chest discomfort","Dyspnoea","Dysgeusia"]}}}